LifeStance Health Group, Inc.

LifeStance Health Group reported strong second-quarter 2026 results, with total revenue increasing significantly by 26.08% to $435.4 million. The company successfully swung to a net income of $23.6 million, a substantial improvement from a net loss in the prior year. Additionally, LifeStance completed three acquisitions and repurchased $97.6 million in common stock during the first half of 2026, demonstrating strategic growth and capital management.

LifeStance Health Group reported strong second-quarter 2026 financial results, with revenue increasing 26% to $435.4 million and net income reaching $23.6 million, a significant improvement from a net loss in the prior year. The company also announced a new $100 million share repurchase program, replacing a previous one. Based on this performance, LifeStance raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA.

LifeStance Health Group reported strong second-quarter 2026 financial results, with revenue increasing 26% year-over-year to $435.4 million and achieving a net income of $23.6 million, a significant improvement from a net loss in the prior year. Adjusted EBITDA surged 94% to $66.0 million. The company also raised its full-year 2026 revenue and Adjusted EBITDA guidance, reflecting continued growth and operational efficiency. Additionally, LifeStance announced a new $100 million share repurchase program.

LifeStance Health Group, Inc. announced it will release its second quarter 2026 earnings before market open on Thursday, August 6, 2026. Following the release, the company will host a live earnings conference call to discuss the results at 8:30 a.m. Eastern Time on the same day. Investors can access the call via dial-in numbers or a real-time audio webcast on the company's Investor Relations website.

LifeStance Health Group, Inc. announced that Jeffrey Rhodes resigned from its Board of Directors and all committees, effective July 2, 2026. His resignation was not due to any disagreement with the company. Concurrently, the Board appointed Thurman Justice, Lori Goltermann, and Safwan Shabab as new directors. Justice and Goltermann were appointed as Class II directors, while Shabab was appointed as a Class III director. Justice and Goltermann each received an initial award of 35,492 restricted stock units.

LifeStance Health Group, Inc. entered into an Underwriting Agreement on May 7, 2026, for an underwritten offering of 35,000,000 shares of its common stock by selling stockholders. The company did not receive any proceeds from this offering. Additionally, LifeStance Health agreed to repurchase 6,000,000 shares from the underwriter at the same price paid to the selling stockholders. The offering closed on May 12, 2026.

LifeStance Health Group announced the pricing of a secondary underwritten public offering of 35,000,000 shares of its common stock at $8.15 per share by certain selling stockholders. The company will not receive any proceeds from this offering. Concurrently, LifeStance has agreed to repurchase 6,000,000 shares from the underwriter at the same price, conditioned upon the completion of the offering. Both the offering and repurchase are expected to close around May 12, 2026.

LifeStance Health Group announced that certain stockholders intend to offer 35,000,000 shares of the company's common stock through a secondary offering. The company itself will not sell any shares or receive any proceeds from this offering. Concurrently, LifeStance has authorized the repurchase of 6,000,000 shares from the underwriter, subject to the completion of the offering.

LifeStance Health Group reported strong first-quarter results for 2026, with total revenue increasing by 21.2% year-over-year to $403.5 million. The company achieved significant growth in net income, reaching $14.2 million, and saw a positive shift in operating cash flow. Additionally, LifeStance Health initiated a $100 million share repurchase program and completed two acquisitions during the quarter.

LifeStance Health Group reported strong financial results for the first quarter ended March 31, 2026, with revenue increasing 21% to $403.5 million and net income rising significantly to $14.2 million. Adjusted EBITDA also saw substantial growth, up 48% to $51.1 million. The company expanded its clinician base by 11% and increased visit volumes by 18%. Following this performance, LifeStance raised its full-year 2026 guidance for revenue, Center Margin, and Adjusted EBITDA, reflecting confidence in its differentiated model and growing demand for mental healthcare.